{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:01:59Z","timestamp":1791810119219,"version":"4.3.4"},"reference-count":68,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,2,28]],"date-time":"2003-02-28T00:00:00Z","timestamp":1046390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2003,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>CD40\u2013CD40 ligand (CD40L) interactions play a significant role in the production of autoantibodies and tissue injury in lupus nephritis. We performed an open\u2010label, multiple\u2010dose study to evaluate the safety, efficacy, and pharmacokinetics of BG9588, a humanized anti\u2010CD40L antibody, in patients with proliferative lupus nephritis. The primary outcome measure was 50% reduction in proteinuria without worsening of renal function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty\u2010eight patients with active proliferative lupus nephritis were scheduled to receive 20 mg\/kg of BG9588 at biweekly intervals for the first 3 doses and at monthly intervals for 4 additional doses. Safety evaluations were performed on all patients. Eighteen patients receiving at least 3 doses were evaluated for efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study was terminated prematurely because of thromboembolic events occurring in patients in this and other BG9588 protocols (2 myocardial infarctions in this study). Of the 18 patients for whom efficacy could be evaluated, 2 had a 50% reduction in proteinuria without worsening of renal function. Mean reductions of 38.9% (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.005), 50.1% (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.005), and 25.3% (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05) in anti\u2013double\u2010stranded DNA (anti\u2010dsDNA) antibody titers were observed at 1, 2, and 3 months, respectively, after the last treatment. There was a significant increase in serum C3 concentrations at 1 month after the last dose (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.005), and hematuria disappeared in all 5 patients with significant hematuria at baseline. There were no statistically significant reductions in lymphocyte count or serum immunoglobulin, anticardiolipin antibody, or rubella IgG antibody concentrations after therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A short course of BG9588 treatment in patients with proliferative lupus nephritis reduces anti\u2010dsDNA antibodies, increases C3 concentrations, and decreases hematuria, suggesting that the drug has immunomodulatory action. Additional studies will be needed to evaluate its long\u2010term effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.10856","type":"journal-article","created":{"date-parts":[[2003,3,18]],"date-time":"2003-03-18T17:50:19Z","timestamp":1048009819000},"page":"719-727","source":"Crossref","is-referenced-by-count":533,"title":["A short course of BG9588 (anti\u2013CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis"],"prefix":"10.1002","volume":"48","author":[{"given":"Dimitrios T.","family":"Boumpas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Furie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Manzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor G.","family":"Illei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Balow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Vaishnaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the BG9588 Lupus Nephritis Trial Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,2,28]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-12-199506150-00009"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1997.365"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199905000-00002"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198412133112402"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198603063141004"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780340803"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199205213262101"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92292-N"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-7-199610010-00003"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-4-200108210-00009"},{"key":"e_1_2_6_12_2","first-page":"275","article-title":"Immunosuppressive therapy in lupus nephritis","volume":"15","author":"D'Cruz D","year":"1997","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(00)70109-0"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/096120339500400205"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1681\/ASN.V104833","article-title":"Mycophenolate mofetil therapy in lupus nephritis: clinical observations","volume":"10","author":"Dooley MA","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200010193431604"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-12-199812150-00007"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199908)42:8<1777::AID-ANR30>3.0.CO;2-C"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02627-1"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80177-6"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1997.162"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/92.4.211"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00832.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10142"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-5-199309010-00003"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1996.528"},{"key":"e_1_2_6_27_2","first-page":"32","article-title":"New prospects for treatment of lupus nephritis","volume":"20","author":"Balow JE","year":"2000","journal-title":"Semin Nephrol"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.154.3.1470"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.5.2158"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.159.7.3104"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.314"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118643"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118855"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400117"},{"key":"e_1_2_6_35_2","first-page":"95","article-title":"Phase I clinical trial of a monoclonal antibody against CD40\u2010ligand (IDEC\u2010131) in patients with systemic lupus erythematosus","volume":"28","author":"Davis JC","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI7014"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1997.102"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.163.4.2168"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.6.3323"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390103"},{"key":"e_1_2_6_41_2","first-page":"1387","article-title":"CD40 antigen is expressed by endothelial cells and tumor cells in Kaposi's sarcoma","volume":"148","author":"Pammer J","year":"1996","journal-title":"Am J Pathol"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.58.2.209"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.1.173"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.6.1857"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350606"},{"key":"e_1_2_6_47_2","first-page":"110","article-title":"Reliability of SELENA SLEDAI and flare as clinical trial outcome measures","volume":"7","author":"Petri M","year":"1998","journal-title":"Lupus"},{"key":"e_1_2_6_48_2","volume-title":"SF\u201036 health survey: manual and interpretation guide","author":"Ware JE","year":"1993"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1191\/096120398678920758"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1191\/096120398678920749"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-2-114"},{"key":"e_1_2_6_52_2","first-page":"2052","article-title":"Response to treatment as a predictor of longterm outcome in patients with lupus nephritis","volume":"21","author":"Fraenkel L","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10273"},{"issue":"9","key":"e_1_2_6_54_2","first-page":"S282","article-title":"Normalization of peripheral B cells following treatment of active SLE patients with humanized anti\u2010CD154 Mab (5C8, BG9588)","volume":"44","author":"Grammer AC","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"9","key":"e_1_2_6_55_2","first-page":"S282","article-title":"Analysis of CD5 expression on peripheral B cells following treatment of active SLE patients with humanized anti\u2010CD154 mAb (5C8, BG9588)","volume":"44","author":"Gur H","year":"2001","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10287"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.3.1740"},{"key":"e_1_2_6_58_2","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.4049\/jimmunol.157.7.3159","article-title":"Anti\u2010CD40 ligand antibody treatment prevents the development of lupus\u2010like nephritis in a subset of New Zealand black \u00d7 New Zealand white mice: response correlates with the absence of an anti\u2010antibody response","volume":"157","author":"Early GS","year":"1996","journal-title":"J Immunol"},{"key":"e_1_2_6_59_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI750"},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI10167"},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)60854-8"},{"key":"e_1_2_6_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/9536"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/361539a0"},{"key":"e_1_2_6_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90668-G"},{"key":"e_1_2_6_65_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119183"},{"key":"e_1_2_6_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/35393"},{"key":"e_1_2_6_67_2","doi-asserted-by":"publisher","DOI":"10.1038\/72162"},{"key":"e_1_2_6_68_2","unstructured":"IDEC PharmaceuticalsWeb site. Accessed Jan. 20 2003. URL:http:\/\/www.idecpharm.com\/site\/science\/idec131.htm."},{"key":"e_1_2_6_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0302-247"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.10856","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.10856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T16:55:41Z","timestamp":1700672141000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.10856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2,28]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["10.1002\/art.10856"],"URL":"https:\/\/doi.org\/10.1002\/art.10856","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2,28]]}}}